Terms: = Germ cell tumor AND LDH AND Treatment
566 results:
1. Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO/deSUMOylation in cerebral ischemia-reperfusion injury.
Chen X; Yang T; Zhou Y; Mei Z; Zhang W
CNS Neurosci Ther; 2024 Apr; 30(4):e14725. PubMed ID: 38615367
[TBL] [Abstract] [Full Text] [Related]
2. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
[TBL] [Abstract] [Full Text] [Related]
3. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
[TBL] [Abstract] [Full Text] [Related]
4. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy.
Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
[TBL] [Abstract] [Full Text] [Related]
5. Survival analysis of comprehensive treatment in Chinese patients with metastatic melanoma: A retrospective analysis.
Chen Q; Zhao Y; Li P; Duan J; Fu X; Tang Y; Ma Y; Zhou Q
Skin Res Technol; 2024 Feb; 30(2):e13546. PubMed ID: 38279601
[TBL] [Abstract] [Full Text] [Related]
6. BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JWWB; Hospers GAP; Kapiteijn E; Bloem M; Piersma D; Stevense-den Boer M; Verheijden RJ; van der Veldt AAM; Wouters MWJM; Blokx WAM; Suijkerbuijk KPM
Cancer; 2024 May; 130(9):1673-1683. PubMed ID: 38198485
[TBL] [Abstract] [Full Text] [Related]
7. Apocynin exerts neuroprotective effects in fumonisin b1-induced neurotoxicity via attenuation of oxidative stress and apoptosis in an animal model.
Krishnaswamy K; Manasa V; Khan MT; Serva Peddha M
J Food Sci; 2024 Feb; 89(2):1280-1293. PubMed ID: 38193205
[TBL] [Abstract] [Full Text] [Related]
8. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
9. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG
Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329
[TBL] [Abstract] [Full Text] [Related]
10. A novel lactate dehydrogenase-based risk score model to predict the prognosis of primary central nervous system germ cell tumor treated with chemoradiotherapy.
Yao DC; Ye BK; Yao DJ; Guo CC
Clin Neurol Neurosurg; 2024 Jan; 236():108081. PubMed ID: 38091701
[TBL] [Abstract] [Full Text] [Related]
11. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
[TBL] [Abstract] [Full Text] [Related]
12. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
[TBL] [Abstract] [Full Text] [Related]
13. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic Value of Lactate Dehydrogenase in Patients with Melanoma Treated with Pembrolizumab.
Popović A; Petković I; Dimitrijevic A; Jović A
Acta Dermatovenerol Croat; 2023 Nov; 31(2):86-91. PubMed ID: 38006368
[TBL] [Abstract] [Full Text] [Related]
15. Xihuang pill facilitates glioma cell pyroptosis via the POU4F1/STAT3 axis.
Tang N; Zhu Y; Yu J
Funct Integr Genomics; 2023 Nov; 23(4):334. PubMed ID: 37962640
[TBL] [Abstract] [Full Text] [Related]
16. Design, synthesis, and evaluation of n-butylphthalide and ligustrazine hybrids as potent neuroprotective agents for the treatment of ischemic stroke in vitro and in vivo.
Jia Y; Xiao H; Wang X; Liu Y; Wang J; Xie H; Shang H; Sun G; Tian Y
Bioorg Chem; 2024 Jan; 142():106961. PubMed ID: 37956636
[TBL] [Abstract] [Full Text] [Related]
17. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
Gambichler T; Iordanou M; Becker JC; Susok L
Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
[TBL] [Abstract] [Full Text] [Related]
18. Yin Yang 1 suppresses apoptosis and oxidative stress injury in SH-SY5Y cells by facilitating NR4A1 expression.
Kang Q; Chai W; Min J; Qu X
J Neurogenet; 2023; 37(4):115-123. PubMed ID: 37922205
[TBL] [Abstract] [Full Text] [Related]
19. Serum cell Division Cycle 42 before and after Programmed Death-1 Inhibitor Therapy in Advanced Melanoma Patients: Correlation with tumor Features, Clinical Response, and Survival.
Zhang L; Zhang S; Han Z; Liu Z; Xu Y; Li X; Miao G; Niu L
Tohoku J Exp Med; 2024 Mar; 262(2):133-141. PubMed ID: 37914283
[TBL] [Abstract] [Full Text] [Related]
20. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D; Woodford R; Menzies AM; Zimmer L; Williamson A; Ramelyte E; Dimitriou F; Wicky A; Wallace R; Mallardo M; Cortellini A; Budillon A; Atkinson V; Sandhu S; Olivier M; Dummer R; Lorigan P; Schadendorf D; Long GV; Simeone E; Ascierto PA
J Transl Med; 2023 Oct; 21(1):753. PubMed ID: 37880788
[TBL] [Abstract] [Full Text] [Related]
[Next]